Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.

de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, Baas F, Versteeg R, Kool M.

Clin Cancer Res. 2008 Jul 1;14(13):4154-60. doi: 10.1158/1078-0432.CCR-07-4159.

2.

Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.

Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M.

Clin Cancer Res. 2007 May 1;13(9):2651-7.

3.

Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.

Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC.

J Neuropathol Exp Neurol. 2004 May;63(5):441-9.

PMID:
15198123
4.

Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.

Grotzer MA, von Hoff K, von Bueren AO, Shalaby T, Hartmann W, Warmuth-Metz M, Emser A, Kortmann RD, Kuehl J, Pietsch T, Rutkowski S.

Klin Padiatr. 2007 Nov-Dec;219(6):312-7.

PMID:
18050040
5.

A clinicobiological model predicting survival in medulloblastoma.

Ray A, Ho M, Ma J, Parkes RK, Mainprize TG, Ueda S, McLaughlin J, Bouffet E, Rutka JT, Hawkins CE.

Clin Cancer Res. 2004 Nov 15;10(22):7613-20.

6.

Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.

von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T, Rutkowski S.

Pediatr Blood Cancer. 2010 Mar;54(3):369-76. doi: 10.1002/pbc.22339.

PMID:
19908297
7.

Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas.

Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL.

J Clin Oncol. 2004 Mar 15;22(6):994-8. Epub 2004 Feb 17.

PMID:
14970184
8.

An immunohistochemical analysis of medulloblastoma and PNET with emphasis on N-myc protein expression.

Moriuchi S, Shimizu K, Miyao Y, Hayakawa T.

Anticancer Res. 1996 Sep-Oct;16(5A):2687-92.

PMID:
8917371
9.

MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.

Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, Sutton LN, Rorke LB, Brodeur GM, Phillips PC.

Clin Cancer Res. 2001 Aug;7(8):2425-33.

10.

Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.

Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ.

J Clin Oncol. 2004 Mar 15;22(6):984-93. Epub 2004 Feb 17.

PMID:
14970185
11.

[Risk stratification in medulloblastoma: screening for molecular markers].

Ebinger M, Senf L, Scheurlen W.

Klin Padiatr. 2006 May-Jun;218(3):139-42. German.

PMID:
16688669
12.

Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.

Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC.

J Clin Oncol. 2011 Apr 10;29(11):1400-7. doi: 10.1200/JCO.2010.30.2810. Epub 2010 Oct 4.

13.

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.

Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P, Deubzer HE, Lodrini M, Taylor MD, von Deimling A, Pfister S, Witt O.

Clin Cancer Res. 2010 Jun 15;16(12):3240-52. doi: 10.1158/1078-0432.CCR-10-0395. Epub 2010 Apr 22.

14.

Correlation of gamma-catenin expression with good prognosis in medulloblastomas.

Misaki K, Marukawa K, Hayashi Y, Fukusato T, Minamoto T, Hasegawa M, Yamashita J, Fujisawa H.

J Neurosurg. 2005 Mar;102(2 Suppl):197-206.

PMID:
16156230
15.

The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.

Pizer BL, Clifford SC.

Br J Neurosurg. 2009 Aug;23(4):364-75. doi: 10.1080/02688690903121807. Review.

PMID:
19637007
16.

Clinical and molecular parameters for risk stratification in Mexican children with medulloblastoma.

López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Siordia-Reyes G, Betanzos-Cabrera Y, Cerecedo-Díaz F, del Angel VW, Diegopérez-Ramírez J.

Arch Med Res. 2007 Oct;38(7):769-73. Epub 2007 Jul 19.

PMID:
17845897
17.

Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.

Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P.

Cancer Res. 2004 May 1;64(9):3103-11.

18.

Pathological and molecular heterogeneity of medulloblastoma.

Gulino A, Arcella A, Giangaspero F.

Curr Opin Oncol. 2008 Nov;20(6):668-75. doi: 10.1097/CCO.0b013e32831369f4. Review.

PMID:
18841049
19.

p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival.

Zitterbart K, Zavrelova I, Kadlecova J, Spesna R, Kratochvilova A, Pavelka Z, Sterba J.

Acta Neuropathol. 2007 Dec;114(6):641-50. Epub 2007 Oct 3. Erratum in: Acta Neuropathol. 2008 Nov;116(5):579-80.

PMID:
17912537
20.

Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis.

de Bont JM, Kros JM, Passier MM, Reddingius RE, Sillevis Smitt PA, Luider TM, den Boer ML, Pieters R.

Neuro Oncol. 2008 Oct;10(5):648-60. doi: 10.1215/15228517-2008-032. Epub 2008 Jun 24.

Supplemental Content

Support Center